Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05916118 · ClinicalTrials.gov registry record · NA

Exercise and Oxaliplatin-induced Peripheral Neuropathy

A NA study of Peripheral Neuropathy, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
10
Enrollment target
2
Study locations

NCT05916118 is a NA study of Peripheral Neuropathy that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 10 participants, below the 80-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05916118, a NA study of Peripheral Neuropathy, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

This single group study was conducted to test the feasibility and acceptability of implementing an exercise intervention during oxaliplatin infusion across three months of oxalipatin-based chemotherapy in patients with gastrointestinal malignancies.10 patients were enrolled onto this study and validated questionnaires were used to evaluate the feasibility and acceptability of the intervention and collect patient-reported outcomes over the course of study enrollment.

Conditions Studied

Interventions

  • OTHER Aerobic Exercise

Study Locations (2)

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon
  • Dartmouth Health - Lebanon

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-10-24
Est. Completion 2023-06-25
Phase NA

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

What the Registry Record Tells You About NCT05916118

The ClinicalTrials.gov registry entry for NCT05916118 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 80-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (87% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Aerobic Exercise is the first listed.

NCT05916118 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Hampshire.

Frequently Asked Questions

What is clinical trial NCT05916118 about?

NCT05916118 is a clinical study titled "Exercise and Oxaliplatin-induced Peripheral Neuropathy". This single group study was conducted to test the feasibility and acceptability of implementing an exercise intervention during oxaliplatin infusion across three months of oxalipatin-based chemotherapy in patients with gastrointestinal malignancies.10 patients were enrolled onto this study and valid...

What is the current status of trial NCT05916118?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2022-10-24. Estimated completion is 2023-06-25.

What conditions does trial NCT05916118 study?

This clinical trial studies the following conditions: Peripheral Neuropathy.

What interventions are being tested in trial NCT05916118?

The interventions under investigation include: Aerobic Exercise (OTHER).

Who is sponsoring clinical trial NCT05916118?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05916118 being conducted?

This trial has 2 study locations across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.